Applications of minimal physiologically-based pharmacokinetic models

Conventional mammillary models are frequently used for pharmacokinetic (PK) analysis when only blood or plasma data are available. Such models depend on the quality of the drug disposition data and have vague biological features. An alternative minimal-physiologically-based PK (minimal-PBPK) modeling approach is proposed which inherits and lumps major physiologic attributes from whole-body PBPK models. The body and model are represented as actual blood and tissue (usually total body weight) volumes, fractions (fd) of cardiac output with Fick’s Law of Perfusion, tissue/blood partitioning (Kp), and systemic or intrinsic clearance. Analyzing only blood or plasma concentrations versus time, the minimal-PBPK models parsimoniously generate physiologically-relevant PK parameters which are more easily interpreted than those from mammillary models. The minimal-PBPK models were applied to four types of therapeutic agents and conditions. The models well captured the human PK profiles of 22 selected beta-lactam antibiotics allowing comparison of fitted and calculated Kp values. Adding a classical hepatic compartment with hepatic blood flow allowed joint fitting of oral and intravenous (IV) data for four hepatic elimination drugs (dihydrocodeine, verapamil, repaglinide, midazolam) providing separate estimates of hepatic intrinsic clearance, non-hepatic clearance, and pre-hepatic bioavailability. The basic model was integrated with allometric scaling principles to simultaneously describe moxifloxacin PK in five species with common Kp and fd values. A basic model assigning clearance to the tissue compartment well characterized plasma concentrations of six monoclonal antibodies in human subjects, providing good concordance of predictions with expected tissue kinetics. The proposed minimal-PBPK modeling approach offers an alternative and more rational basis for assessing PK than compartmental models.

[1]  S. Kety The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[2]  E. M. Renkin Effects of blood flow on diffusion kinetics in isolated, perfused hindlegs of cats; a double circulation hypothesis. , 1955, The American journal of physiology.

[3]  E. M. Renkin Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. , 1959, The American journal of physiology.

[4]  C. Crone,et al.  THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.

[5]  M. Rowland,et al.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. , 1968, Journal of pharmaceutical sciences.

[6]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[7]  A. Goldstein,et al.  The Fundamental Concepts of Pharmacology. (Book Reviews: Principles of Drug Action. The Basis of Pharmacology) , 1970 .

[8]  M. Barza,et al.  SOME DETERMINANTS OF THE DISTRIBUTION OF PENICILLINS AND CEPHALOSPORINS IN THE BODY. PRACTICAL AND THEORETICAL CONSIDERATIONS * , 1974, Annals of the New York Academy of Sciences.

[9]  A. Karim The pharmacokinetics of Norpace. , 1975, Angiology.

[10]  M. Barza,et al.  Comparative Pharmacokinetics of Cefamandole, Cephapirin, and Cephalothin in Healthy Subjects and Effect of Repeated Dosing , 1976, Antimicrobial Agents and Chemotherapy.

[11]  W. Jusko,et al.  Pharmacokinetics of methicillin in patients with cystic fibrosis. , 1977, The Journal of infectious diseases.

[12]  E. M. Renkin Multiple pathways of capillary permeability. , 1977, Circulation research.

[13]  D. Spyker,et al.  Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function , 1979, Antimicrobial Agents and Chemotherapy.

[14]  M. Pfeffer,et al.  Comparative Pharmacokinetics of Ceforanide (BL-S786R) and Cefazolin in Laboratory Animals and Humans , 1980, Antimicrobial Agents and Chemotherapy.

[15]  S. Barriere,et al.  Pharmacokinetics of mecillinam in health subjects , 1980, Antimicrobial Agents and Chemotherapy.

[16]  B. Meyers,et al.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics , 1980, Antimicrobial Agents and Chemotherapy.

[17]  P. Welling,et al.  Mezlocillin Pharmacokinetics After Single Intravenous Doses to Patients with Varying Degrees of Renal Function , 1980, Antimicrobial Agents and Chemotherapy.

[18]  R. Wise,et al.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. , 1980, The Journal of infectious diseases.

[19]  D. Kampf,et al.  Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency , 1981, Antimicrobial Agents and Chemotherapy.

[20]  W J Jusko,et al.  Prednisolone metabolism and excretion in the isolated perfused rat kidney. , 1981, Drug metabolism and disposition: the biological fate of chemicals.

[21]  W. Jusko,et al.  Distribution volume related to body weight and protein binding. , 1982, Journal of pharmaceutical sciences.

[22]  E. S. Waller,et al.  The Effect of Probenecid on Nafcillin Disposition , 1982, Journal of clinical pharmacology.

[23]  P Heizmann,et al.  Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.

[24]  M. Pfeffer,et al.  Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine , 1983, Antimicrobial Agents and Chemotherapy.

[25]  P. McNamara,et al.  Fraction unbound in interstitial fluid. , 1983, Journal of pharmaceutical sciences.

[26]  R. Blouin,et al.  Clinical Pharmacokinetics of Verapamil , 1984, Clinical pharmacokinetics.

[27]  M. Eichelbaum,et al.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. , 1984, British journal of clinical pharmacology.

[28]  Griaznova Ns,et al.  [Penicillin-binding proteins. Their enzymatic activity and properties]. , 1986 .

[29]  B. Winblad,et al.  Single-dose pharmacokinetics of dicloxacillin in healthy subjects of young and old age. , 1986, Scandinavian journal of infectious diseases.

[30]  M. Dudley,et al.  Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans , 1986, Antimicrobial Agents and Chemotherapy.

[31]  L. A. Beightol,et al.  Comparative pharmacokinetics of azlocillin and piperacillin in normal adults , 1986, Antimicrobial Agents and Chemotherapy.

[32]  O. Cars Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[33]  C A Shanks,et al.  Minimal compartmental model of circulatory mixing of indocyanine green. , 1992, The American journal of physiology.

[34]  B. Gunter,et al.  Effects of a TV Drama Series upon Public Impressions about Psychiatrists , 1994, Psychological reports.

[35]  M. Avram,et al.  A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs. , 1994, The Journal of pharmacology and experimental therapeutics.

[36]  B. Haraldsson,et al.  Transport of macromolecules across microvascular walls: the two-pore theory. , 1994, Physiological reviews.

[37]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[38]  P. du Souich,et al.  Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. , 2003, British journal of clinical pharmacology.

[39]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[40]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[41]  L. Lidgren,et al.  Pharmacokinetics of cloxacillin in patients undergoing hip or knee replacement , 1997, European Journal of Clinical Pharmacology.

[42]  R. Junghans Finally! the Brambell receptor (FcRB) , 1997, Immunologic research.

[43]  D. Greenblatt,et al.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.

[44]  I. Tamai,et al.  Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. , 1999, Journal of pharmaceutical sciences.

[45]  C. Kohlsdorfer,et al.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. , 1999, The Journal of antimicrobial chemotherapy.

[46]  Michael P. Jones,et al.  Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans , 2000, Journal of clinical pharmacology.

[47]  G Benoni,et al.  Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. , 2001, Journal of pharmaceutical sciences.

[48]  J. Ghuysen Penicillin‐Binding Proteins , 2002 .

[49]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[50]  J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[51]  D. Levitt,et al.  The pharmacokinetics of the interstitial space in humans , 2003, BMC clinical pharmacology.

[52]  W. Jusko,et al.  Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. , 2003, Journal of pharmaceutical sciences.

[53]  M. Roberts,et al.  The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin , 2004, European Journal of Clinical Pharmacology.

[54]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[55]  M. Weiss Modelling of initial distribution of drugs following intravenous bolus injection , 2004, European Journal of Clinical Pharmacology.

[56]  P. Vicini,et al.  Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors , 2004, Clinical Cancer Research.

[57]  M. Roberts,et al.  The effect of posture on the pharmacokinetics of intravenous benzylpenicillin , 2004, European Journal of Clinical Pharmacology.

[58]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of pharmacokinetics and biopharmaceutics.

[59]  F. Rowell,et al.  Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites , 2004, European Journal of Clinical Pharmacology.

[60]  W. L. Chiou Potential pitfalls in the conventional pharmacokinetic studies: Effects of the initial mixing of drug in blood and the pulmonary first-pass elimination , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[61]  A. Atkinson,et al.  Analysis of the contributions of permeability and flow to intercompartmental clearance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[62]  Malcolm Rowland,et al.  Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[63]  Harold Boxenbaum,et al.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[64]  D. P. Vaughan,et al.  Applications of a recirculatory stochastic pharmacokinetic model: Limitations of compartmental models , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[65]  P. Parren,et al.  Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.

[66]  K Rowland-Yeo,et al.  Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[67]  U. Holzgrabe,et al.  Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers , 2007, Antimicrobial Agents and Chemotherapy.

[68]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[69]  Y. Tsukamoto,et al.  A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. , 2007, British journal of clinical pharmacology.

[70]  U. Holzgrabe,et al.  Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin , 2007, Antimicrobial Agents and Chemotherapy.

[71]  S. Cox Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. , 2007, Journal of veterinary pharmacology and therapeutics.

[72]  N. Lehn,et al.  Tissue concentrations of vancomycin and Moxifloxacin in periprosthetic infection in rats , 2007, Acta orthopaedica.

[73]  L. Giot,et al.  A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. , 2008, International journal of clinical pharmacology and therapeutics.

[74]  J. Widness,et al.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. , 2008, The Journal of pharmacy and pharmacology.

[75]  J. Hoffman Practical and Theoretical Considerations , 2009 .

[76]  W. White,et al.  Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. , 2009, Clinical therapeutics.

[77]  Yuichi Sugiyama,et al.  Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.

[78]  Y. Nasuhara,et al.  Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in Healthy Volunteers Given Half-Hour and Three-Hour Intravenous Infusions , 2009, Antimicrobial Agents and Chemotherapy.

[79]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[80]  Wilhelm Huisinga,et al.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[81]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[82]  H. Wakelee,et al.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  Jianghua Chen,et al.  Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts , 2010, mAbs.

[84]  Yuichi Sugiyama,et al.  Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[85]  K. Fujiwara,et al.  Immunocytochemistry for Amoxicillin and Its Use for Studying Uptake of the Drug in the Intestine, Liver, and Kidney of Rats , 2010, Antimicrobial Agents and Chemotherapy.

[86]  Daniel A. Beard,et al.  Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[87]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[88]  D. Choi,et al.  Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[89]  John C. Davis,et al.  Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial , 2012, Arthritis Research & Therapy.

[90]  S. Haddad,et al.  In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. , 2012, Journal of pharmaceutical sciences.

[91]  H. Lode,et al.  Pharmacokinetics of Temocillin in Volunteers , 2012, Drugs.

[92]  W. Huisinga,et al.  Modeling Interindividual Variability in Physiologically Based Pharmacokinetics and Its Link to Mechanistic Covariate Modeling , 2012, CPT: pharmacometrics & systems pharmacology.

[93]  Qingpu Wang,et al.  Comparison of c-Nd:YVO4/YVO4 raman lasers and c-Nd:YVO4 self-Raman lasers , 2012 .

[94]  H. Lennernäs,et al.  The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. , 2012, Molecular pharmaceutics.